LeukoDx is a medical devices company that has developed a diagnostic platform that provides actionable diagnostics, or critical diagnostic information within minutes at the point of care. The company’s product uses flurocytometry technology, where a small sample of the patient’s blood is exposed to incident light and is analyzed for intrinsic and labeled fluorescence that serve as disease-specific identifiers. The patient’s blood sample analysis is processed by an electronic disposable cartridge that produces results in minutes, providing physicians with essential information at the point of care necessary for immediate treatment plans. The company is developing its technology for detection targeting infection/sepsis as its first application. Urinary tract infections and HIV progression can be natural follow-on products establishing a line of cartridge based test running on the same reader. These tests currently require central laboratory tests that do not produce results for hours, even when ordered on a stat basis. The company is currently completing its first round of funding and projects market launch of its product within the next three years.